Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.
Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Malfertheiner P, et al. Among authors: axon at. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084. Gut. 2012. PMID: 22491499 Free article.
Symposium: Helicobacter pylori and clinical risks--focus on gastro-oesophageal reflux disease.
Malfertheiner P, O'Connor HJ, Genta RM, Unge P, Axon AT. Malfertheiner P, et al. Among authors: axon at. Aliment Pharmacol Ther. 2002 Jun;16 Suppl 3:1-10. doi: 10.1046/j.1365-2036.16.s3.1.x. Aliment Pharmacol Ther. 2002. PMID: 12000312 Free article.
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. ...It was felt that prospective, multicentre studies are needed to …
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associate …
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Nyssen OP, et al. Among authors: axon atr. Gut. 2021 Jan;70(1):40-54. doi: 10.1136/gutjnl-2020-321372. Epub 2020 Sep 21. Gut. 2021. PMID: 32958544 Free article.
Panel discussion: breaking the link--clinical options to minimize risk.
Blaser MJ, Kuipers EJ, Ernst P, Axon A, Mégraud F. Blaser MJ, et al. Among authors: axon a. Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:19-23. doi: 10.1046/j.1365-2036.1999.00004.x. Aliment Pharmacol Ther. 1999. PMID: 10209683 Free article. No abstract available.
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Mason J, Axon AT, Forman D, Duffett S, Drummond M, Crocombe W, Feltbower R, Mason S, Brown J, Moayyedi P; Leeds HELP Study Group. Mason J, et al. Among authors: axon at. Aliment Pharmacol Ther. 2002 Mar;16(3):559-68. doi: 10.1046/j.1365-2036.2002.01204.x. Aliment Pharmacol Ther. 2002. PMID: 11876711 Free article. Clinical Trial.
400 results